276 related articles for article (PubMed ID: 9265631)
21. The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis.
Moran RG; Baldwin SW; Taylor EC; Shih C
J Biol Chem; 1989 Dec; 264(35):21047-51. PubMed ID: 2592365
[TBL] [Abstract][Full Text] [Related]
22. Protein structure-based design, synthesis, and biological evaluation of 5-thia-2,6-diamino-4(3H)-oxopyrimidines: potent inhibitors of glycinamide ribonucleotide transformylase with potent cell growth inhibition.
Varney MD; Palmer CL; Romines WH; Boritzki T; Margosiak SA; Almassy R; Janson CA; Bartlett C; Howland EJ; Ferre R
J Med Chem; 1997 Aug; 40(16):2502-24. PubMed ID: 9258357
[TBL] [Abstract][Full Text] [Related]
23. Tetrahydrohomofolate polyglutamates as inhibitors of thymidylate synthase and glycinamide ribonucleotide formyltransferase in Lactobacillus casei.
Thorndike J; Kisliuk RL; Gaumont Y; Piper JR; Nair MG
Arch Biochem Biophys; 1990 Mar; 277(2):334-41. PubMed ID: 2106831
[TBL] [Abstract][Full Text] [Related]
24. Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function.
Bronder JL; Moran RG
Cancer Res; 2002 Sep; 62(18):5236-41. PubMed ID: 12234990
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier.
Zhao R; Gao F; Babani S; Goldman ID
Clin Cancer Res; 2000 Aug; 6(8):3304-11. PubMed ID: 10955817
[TBL] [Abstract][Full Text] [Related]
26. Towards structure-based drug design: crystal structure of a multisubstrate adduct complex of glycinamide ribonucleotide transformylase at 1.96 A resolution.
Klein C; Chen P; Arevalo JH; Stura EA; Marolewski A; Warren MS; Benkovic SJ; Wilson IA
J Mol Biol; 1995 May; 249(1):153-75. PubMed ID: 7776369
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the kinetic mechanism of Escherichia coli glycinamide ribonucleotide transformylase.
Shim JH; Benkovic SJ
Biochemistry; 1998 Jun; 37(24):8776-82. PubMed ID: 9628739
[TBL] [Abstract][Full Text] [Related]
28. Induction of HL-60 leukemia cell differentiation by tetrahydrofolate inhibitors of de novo purine nucleotide biosynthesis.
Sokoloski JA; Beardsley GP; Sartorelli AC
Cancer Chemother Pharmacol; 1991; 28(1):39-44. PubMed ID: 2040032
[TBL] [Abstract][Full Text] [Related]
29. Cellular folates prevent polyglutamation of 5, 10-dideazatetrahydrofolate. A novel mechanism of resistance to folate antimetabolites.
Tse A; Moran RG
J Biol Chem; 1998 Oct; 273(40):25944-52. PubMed ID: 9748271
[TBL] [Abstract][Full Text] [Related]
30. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.
Laohavinij S; Wedge SR; Lind MJ; Bailey N; Humphreys A; Proctor M; Chapman F; Simmons D; Oakley A; Robson L; Gumbrell L; Taylor GA; Thomas HD; Boddy AV; Newell DR; Calvert AH
Invest New Drugs; 1996; 14(3):325-35. PubMed ID: 8958188
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of antineoplastic activity of 5-fluorouracil in mice bearing colon 38 tumor by (6R)5,10-dideazatetrahydrofolic acid.
Pizzorno G; Davis SJ; Hartigan DJ; Russello O
Biochem Pharmacol; 1994 Jun; 47(11):1981-8. PubMed ID: 7516657
[TBL] [Abstract][Full Text] [Related]
32. AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase.
Boritzki TJ; Barlett CA; Zhang C; Howland EF
Invest New Drugs; 1996; 14(3):295-303. PubMed ID: 8958185
[TBL] [Abstract][Full Text] [Related]
33. Role of membrane-associated folate binding protein in the cytotoxicity of antifolates in KB, IGROV1, and L1210A cells.
Schultz RM; Andis SL; Shackelford KA; Gates SB; Ratnam M; Mendelsohn LG; Shih C; Grindey GB
Oncol Res; 1995; 7(2):97-102. PubMed ID: 7579732
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and antifolate activity of 5-methyl-5,10-dideaza analogues of aminopterin and folic acid and an alternative synthesis of 5,10-dideazatetrahydrofolic acid, a potent inhibitor of glycinamide ribonucleotide formyltransferase.
Piper JR; McCaleb GS; Montgomery JA; Kisliuk RL; Gaumont Y; Thorndike J; Sirotnak FM
J Med Chem; 1988 Nov; 31(11):2164-9. PubMed ID: 3184124
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of HKSV28 cell growth by 5,11-methenyl-tetrahydrohomofolate.
Slieker LJ; Benkovic SJ
Mol Pharmacol; 1984 Mar; 25(2):294-302. PubMed ID: 6700575
[TBL] [Abstract][Full Text] [Related]
36. Mammalian glycinamide ribonucleotide transformylase. Kinetic mechanism and associated de novo purine biosynthetic activities.
Caperelli CA
J Biol Chem; 1989 Mar; 264(9):5053-7. PubMed ID: 2925682
[TBL] [Abstract][Full Text] [Related]
37. Quantitation of folic acid enhancement of antifolate synergism.
Gaumont Y; Kisliuk RL; Parsons JC; Greco WR
Cancer Res; 1992 Apr; 52(8):2228-35. PubMed ID: 1532766
[TBL] [Abstract][Full Text] [Related]
38. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line.
Wang Y; Zhao R; Goldman ID
Biochem Pharmacol; 2003 Apr; 65(7):1163-70. PubMed ID: 12663051
[TBL] [Abstract][Full Text] [Related]
39. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport.
Matherly LH; Angeles SM; McGuire JJ
Biochem Pharmacol; 1993 Dec; 46(12):2185-95. PubMed ID: 7506026
[TBL] [Abstract][Full Text] [Related]
40. The apo and ternary complex structures of a chemotherapeutic target: human glycinamide ribonucleotide transformylase.
Dahms TE; Sainz G; Giroux EL; Caperelli CA; Smith JL
Biochemistry; 2005 Jul; 44(29):9841-50. PubMed ID: 16026156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
